The discovery of RNA interference (RNAi), an endogenous cellular gene-silencing
mechanism, has already provided a powerful tool for basic science researchers
to study gene function. The subsequent finding that RNAi also operates in
mammalian cells has generated excitement regarding potential therapeutic applications.
In this article we discuss the basic mechanism of RNAi and the therapeutic
opportunities and obstacles for harnessing RNAi for therapy of human disease.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Gene silencing by RNA interference can be initiated by introducing synthetic
small interfering RNAs (siRNAs) or their precursors into cells where they
are taken up by the endogenous microRNA processing machinery. The siRNA precursors
are cleaved by the Dicer enzyme into siRNAs, which are 19- to 21-nucleotide
double-stranded RNAs with a 2- to 3-nucleotide overhang and characteristic
5′-phosphate and 3′-hydroxyl groups at each end. As Dicer, an
RNAse III–like enzyme, hands off the siRNA to the RISC (the cellular
complex ultimately responsible for “slicing” messenger RNA [mRNA]),
the double-stranded RNA unwinds, the RISC becomes activated, and 1 strand
(the guide strand) remains within the activated complex. If the guide strand
is homologous to an mRNA sequence, Argonaute 2, an enzyme within the RISC
complex, cleaves the mRNA in the center of the region of homology. The cleaved
mRNA is rapidly degraded and the protein for which it encodes is not produced.
The guide strand small RNA is protected from degradation by the RISC and can
direct the cleavage of many mRNAs. Alternately, plasmids or viral vectors
encoding small stem-loop RNAs (called short hairpin RNAs [shRNAs]) can be
introduced into cells where they are incorporated into the cell’s genome,
resulting in the expression of shRNAs that are processed in the nucleus by
the same mechanism as endogenous microRNA precursors and exported to the cytoplasm
where they are processed similarly to the process described above.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 92
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.